Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Studies from St. Louis University yield new information about tuberculosis
December 10th, 2008
According to a study from the United States, "One strategy for improving anti-tuberculosis (TB) vaccination involves the use of recombinant bacille Calmette-Guerin (rBCG) overexpressing protective TB antigens. rBCG30, which overexpresses the Mycobacterium tuberculosis secreted antigen Ag85b, was the first rBCG shown to induce significantly greater protection against TB in animals than parental BCG. We report here the first double-blind phase 1 trial of rBCG30 in 35 adults randomized to receive either rBCG30 or parental Tice BCG intradermally." "Clinical reactogenicity was assessed, and state-of-the-art immunological assays were used to study Ag85b-specific immune...
Source: Vaccine Weekly (2008-12-10)
|
